6533b870fe1ef96bd12d06d7

RESEARCH PRODUCT

TMPRSS4: a novel tumor prognostic indicator for the stratification of stage IA tumors and a liquid biopsy biomarker for NSCLC patients

Cristina SainzCarmen BehrensRuben PioMiriam RedradoAlfonso CalvoAna RemirezEloisa Jantus-lewintreFrancisco ExpositoLuis M. MontuengaCarlos E. De AndreaIgnacio I. WistubaMaria VillalbaCarlos CampsMaria J. PajaresMaria D. Lozano

subject

OncologyTMPRSS4medicine.medical_specialtyDNA methylation NSCLC TMPRSS4 liquid biopsy prognosisTNM staging systemNSCLCArticle03 medical and health sciences0302 clinical medicineInternal medicinemedicineStage (cooking)Liquid biopsyLung cancer030304 developmental biology0303 health sciencesDNA methylationliquid biopsymedicine.diagnostic_testLiquid biopsybusiness.industryGeneral MedicineMethylationmedicine.diseasePrognosisBronchoalveolar lavage030220 oncology & carcinogenesisDNA methylationBiomarker (medicine)prognosisbusiness

description

Relapse rates in surgically resected non-small-cell lung cancer (NSCLC) patients are between 30% and 45% within five years of diagnosis, which shows the clinical need to identify those patients at high risk of recurrence. The eighth TNM staging system recently refined the classification of NSCLC patients and their associated prognosis, but molecular biomarkers could improve the heterogeneous outcomes found within each stage. Here, using two independent cohorts (MDA and CIMA-CUN) and the eighth TNM classification, we show that TMPRSS4 protein expression is an independent prognostic factor in NSCLC, particularly for patients at stage I: relapse-free survival (RFS) HR, 2.42 (95% CI, 1.47&ndash

yearjournalcountryeditionlanguage
2019-12-03
https://hdl.handle.net/10171/62302